Depression PHQ-9

From PatientRecovery
Jump to: navigation, search

The first two Depression questions (Q15 and Q16) are called the Patient Health Questionnaire-2 (PHQ-2). They are also the same first two question in the Depression PHQ-9.

Return to the CDC Health Risk Assessments or Patient Well-Being Assessment

Over the last 2 weeks, how often have you been bothered by the following problems? Not at all Several days Over half the days Nearly every day
1. Little interest or pleasure doing things 0 1 2 3
2. Feeling down, depressed, or hopeless 0 1 2 3
3. Trouble failing asleep, or sleeping too much 0 1 2 3
4. Feeling tired or having little energy 0 1 2 3
5. Poor appetite or overeating 0 1 2 3
6. Feeling bad about yourself - or that you are a failure or have let yourself or your family down 0 1 2 3
7. Trouble concentrating on things, such as reading the newspaper or watching television 0 1 2 3
8. Moving or speaking so slowly that other people could have noticed? Or the opposite - being so fidgety or restless that you have been moving around a lot more than usual 0 1 2 3
9. Thoughts that you would be better off dead or of hurting yourself in some way 0 1 2 3
Total the score _____ + _____ + _____ + _____
=Total Score _____

If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?
□ Not difficult at all
□ Somewhat difficult
□ Very difficult
□ Extremely difficult

Interpreting PHQ-9 Scores

Diagnosis Total Score For Score Suggested Action
Minimal depression 0-4 ≤ 4 The score suggests the patient may not need depression treatment
Mild depression
Moderate depression
5-9
10-14
5-14 Physician uses clinical judgement about treatment, based on patient's duration of symptoms and functional impairment
Moderately severe depression
Severe depression
15-19
20-27
> 14 Warrants treatment for depression, using antidepressant, psychotherapy and/or combination of treatment

The PHQ-9 is described in more detail at the Pfizer website.